Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 2Thrombocythemia, Essential 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroblastoma 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1

Interventions

fludarabine phosphate 20Peripheral Blood Stem Cell Transplantation 20Cyclophosphamide 17Busulfan 16ruxolitinib 14Tacrolimus 12Whole-Body Irradiation 9Mycophenolic Acid 9Methotrexate 8Antilymphocyte Serum 8Cyclosporine 7peginterferon alfa-2a 6Hydroxyurea 6Filgrastim 6Etoposide 6Aspirin 6fludarabine 5Prednisone 5Melphalan 5Imatinib Mesylate 5Cytarabine 5Decitabine 4pomalidomide 3givinostat hydrochloride 3givinostat 3Topotecan 3Thiotepa 3Radiotherapy 3Lenalidomide 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Polycythemia Vera × lestaurtinib × Clear all
NCT00586651 2015-10-08

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
39 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡